Nat Rev Immunol 10:345–352īeste G, Schmidt FS, Stibora T, Skerra A (1999) Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. mAbs 3:107–110īeck A, Wurch T, Bailly C, Corvaia N (2010) Strategies and challenges for the next generation of therapeutic antibodies. J Nucl Med 51:892–897īeck A (2011) Biosimilar, biobetter and next generation therapeutic antibodies. Curr Opin Mol Ther 11:22–30īaum RP, Prasad V, Muller D, Schuchardt C, Orlova A, Wennborg A, Tolmachev V, Feldwisch J (2010) Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. Cancer Res 69:4941–4944īäuerle PA, Kufer P, Bargou R (2009) BiTE: teaching antibodies to engage T-cells for cancer therapy. Protein Eng 15:1015–1020īäuerle PA, Reinhardt C (2009) Bispecific T-cell engaging antibodies for cancer therapy. Mol Cancer Ther 12:B123īatori V, Koide A, Koide S (2002) Exploring the potential of the monobody scaffold: effects of loop elongation on the stability of a fibronectin type III domain. J Cardiovasc Transl Res 6:355–363īatey S, Leung K, Rowlands R, Isaac S, Carvalho J, Weller S, Wydro M, Gaspar M, Medcalf M, Pegram R, Drewett V, Tuna M, Haurum J, Sun HH (2013) Preclinical evaluation of FS102: a HER2-specific Fcab with a novel mechanism of action. J Immunol 187:4913–4919īartunek J, Barbato E, Heyndrickx G, Vanderheyden M, Wijns W, Holz JB (2013) Novel antiplatelet agents: ALX-0081, a Nanobody directed towards von Willebrand factor. Cardiovasc Diabetol 12:148īarratt-Due A, Thorgersen EB, Lindstad JK, Pharo A, Lissina O, Lambris JD, Nunn MA, Mollnes TE (2011) Ornithodoros moubata complement inhibitor is an equally effective C5 inhibitor in pigs and humans. Nat Rev Drug Discov 2:693–694īao W, Holt LJ, Prince RD, Jones GX, Aravindhan K, Szapacs M, Barbour AM, Jolivette LJ, Lepore JJ, Willette RN, DeAngelis E, Jucker BM (2013) Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat. J Mol Biol 273:927–948Īrndt KM, Müller KM, Plückthun A (1998) Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment. SubmittedĪl-Lazikani B, Lesk AM, Chothia C (1997) Standard conformations for the canonical structures of immunoglobulins. Anticalins directed against the fibronectin extra domain B (ED-B) as diagnostic tracers for glioblastomas. Blood 122:360Īlbrecht V, Richter A, Pfeiffer S, Gebauer M, Lindner S, Gieser E, Schüller U, Schichor C, Gildehaus FJ, Bartenstein P, Tonn JC, Skerra A, Glass R. Landes Bioscience, GeorgetownĪL Hussaini MH, Ritchey J, Rettig MP, Eissenberg L, Uy GL, Chichili G, Moore PA, Johnson S, Collins L, Bonvini E, DiPersio JF (2013) Targeting CD123 in leukemic stem cells using dual affinity re-targeting molecules (DARTs ®). Åkerström B, Borregaard N, Flower DA, Salier J-S (2006) Lipocalins. This process is experimental and the keywords may be updated as the learning algorithm improves.Īhlgren S, Orlova A, Wållberg H, Hansson M, Sandström M, Lewsley R, Wennborg A, Abrahmsen L, Tolmachev V, Feldwisch J (2010) Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. These keywords were added by machine and not by the authors. The four most advanced scaffold technologies, Adnectins, Affibodies, Anticalins and DARPins, which were developed beyond the academic research stage and have reached clinical studies, constitute another focus of this review. These engineered “protein scaffolds”, which are based on non-immunoglobulin proteins furnished with novel binding sites, offer improved manufacturability, facilitate new functional combinations and, thus, likely enable unique therapeutic modes of action to yield promising biobetters. Apart from established Ig fragments such as Fabs, scFvs and domain antibodies, alternative binding proteins are increasingly exploited as therapeutics. Bispecifics such as BiTEs and DARTs offer high potency due to a novel mode of action but involve complicated construction. Currently, the challenge is to create next generation types of antibodies that offer improvements over classical MAbs with regard to biomolecular attributes and clinical performance. This review summarizes crucial events during the development of this expanding field, with emphasis on recent advances in the design and manipulation of functional Ig fragments for therapeutic applications. Antibody technology has gone through a long evolution.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |